Overview

A Study of r-PA Treating Patients With Acute Ischemic Stroke

Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.
Phase:
Phase 3
Details
Lead Sponsor:
Angde Biotech Pharmaceutical Co., Ltd.
Collaborator:
Beijing Tiantan Hospital
Treatments:
Plasminogen
Reteplase
Tissue Plasminogen Activator